Abstract | OBJECTIVE: METHODS: We evaluated 34 patients who were tested for NMO- IgG between 2000 and 2007 and who had two or more episodes of ON without satisfying a diagnosis of MS or NMO prior to serologic testing. Clinical data were available for 25 Mayo Clinic patients (5 NMO- IgG positive and 20 NMO- IgG negative) and for an additional 9 seropositive patients whose serum was referred to the Mayo Clinic Neuroimmunology laboratory for testing. RESULTS: Twenty percent of the patients with recurrent ON seen at Mayo Clinic were seropositive. All NMO- IgG-positive patients (vs 65% NMO- IgG-negative patients) had at least one attack with visual acuity in the affected eye worse than 20/200 (p = 0.05). In seropositive patients for whom long-term follow-up was possible (median 8.9 years after the initial ON), 6 of 12 (50%) experienced an episode of myelitis and fulfilled criteria for NMO. In contrast, 1 of 15 seronegative patients (6.7%) fulfilled McDonald criteria for MS (p = 0.03). Seropositive patients had a final visual score which was worse than that of seronegative patients (p = 0.02). CONCLUSIONS:
|
Authors | M Matiello, V A Lennon, A Jacob, S J Pittock, C F Lucchinetti, D M Wingerchuk, B G Weinshenker |
Journal | Neurology
(Neurology)
Vol. 70
Issue 23
Pg. 2197-200
(Jun 03 2008)
ISSN: 1526-632X [Electronic] United States |
PMID | 18434643
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Autoantibodies
- Immunoglobulin G
|
Topics |
- Adolescent
- Adult
- Autoantibodies
(blood)
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin G
(blood)
- Magnetic Resonance Imaging
- Male
- Neuromyelitis Optica
(diagnosis, immunology, prevention & control)
- Optic Neuritis
(diagnosis, immunology, prevention & control)
- Predictive Value of Tests
- Secondary Prevention
- Treatment Outcome
|